01—Abstract
Summary
Summary of the 10-K filed February 17, 2010. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics Incorporated's 2009 Form 10-K highlights a company firmly established as the world leader in diagnostic testing, information, and services.
For the fiscal year ended December 31, 2009, the company reported net revenues of $7.5 billiona, processing approximately 148 million test requisitions. Quest Diagnostics' strategy focuses on delivering a superior patient experience, driving quality through Six Sigma, leveraging its extensive assets, and leading in medical innovation and IT solutions. The company detailed its growth in specialized testing areas like gene-based and esoteric testing, and anatomic pathology, noting significant strength in cancer diagnostics following the acquisition of AmeriPath.
Financially, the company demonstrated resilience, with income from continuing operations growing to $730 millionb, or $3.88 per diluted share, up from $632 million, or $3.22 per diluted share, in 2008. This growth was supported by improved operating performance, lower interest expenses, and actions to enhance operational efficiency.
The company also continued its commitment to shareholder returns through dividends and share repurchases. Despite economic challenges, Quest Diagnostics maintained a strong market position, driven by its comprehensive test menu, extensive network, and commitment to innovation and quality.
02—Key points
Key Highlights
- Quest Diagnostics processed approximately 148 million test requisitions in 2009, generating $7.5 billion in net revenues.
- The company reported income from continuing operations of $730 million ($3.88 per diluted share) in 2009, an increase from $632 million ($3.22 per diluted share) in 2008.
- Key strategic priorities include enhancing the patient experience, maintaining Six Sigma quality, leveraging assets, and driving innovation in medical and IT solutions.
- Quest Diagnostics is a leader in specialized testing areas such as gene-based, esoteric, and anatomic pathology testing, particularly in cancer diagnostics.
- The company actively pursued debt reduction and share repurchases, demonstrating a commitment to financial flexibility and shareholder value.
- Quest Diagnostics continued to invest in healthcare information technology, aiming to improve patient care and streamline workflows through solutions like the Care360 suite.
- Despite a challenging economic environment, the company's financial performance showed improvement, driven by revenue growth and cost-efficiency initiatives.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2009, Quest Diagnostics Inc kept $0.10.
- Revenue$7.46B100.0%
- Cost of revenue−$4.32B58.0%
- Gross profit$3.13B42.0%
- Operating costs−$1.77B23.8%
- Operating income$1.36B18.2%
- Interest, other & tax−$630.0M8.5%
- Net income$729.1M9.8%
Where FY2009 revenue went
$7.46B- Cost of revenue: $4.32B, 58% of revenue
- SG&A: $1.75B, 23% of revenue
- Net income: $729.1M, 9.8% of revenue
- Interest, other & tax: $630.0M, 8.5% of revenue
Kept 9.8% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2009filed February 17, 2010Financial Statements
FY2009 against FY2008
| Line item | FY2009FY2008 | Change |
|---|---|---|
| Revenue | $7.46B$7.25B | +2.8% |
| Cost of Revenue | $4.32B$4.26B | +1.5% |
| Gross Profit | $3.13B$2.99B | +4.7% |
| SG&A Expenses | $1.75B$1.74B | +0.6% |
| Operating Expenses | $6.10B$6.03B | +1.1% |
| Operating Income | $1.36B$1.22B | +11.2% |
| Interest Expense | $146.59M-$185.48M | +179.0% |
| Net Income | $729.11M$581.49M | +25.4% |
| EPS (Basic) | $3.91$2.99 | +30.8% |
| EPS (Diluted) | $3.87$2.96 | +30.7% |
| Shares Outstanding (Basic) | 185.95M194.28M | −4.3% |
| Shares Outstanding (Diluted) | 187.80M195.96M | −4.2% |
05—Questions
Frequently Asked Questions
What was Quest Diagnostics' financial performance in 2009?
In 2009, Quest Diagnostics reported net revenues of $7.5 billion and income from continuing operations of $730 million ($3.88 per diluted share), representing an increase from the previous year's $632 million ($3.22 per diluted share). This growth was attributed to improved operating performance, cost-efficiency measures, and lower interest expenses.
What are Quest Diagnostics' main strategic initiatives?
Quest Diagnostics' strategy focuses on several key areas: delivering a superior patient experience, maintaining high quality through Six Sigma processes, leveraging its extensive network and capabilities, leading in medical innovation, expanding its geographic reach, and broadening its diagnostic scope. The company also emphasizes investing in healthcare information technology solutions.
How did acquisitions impact Quest Diagnostics in 2009?
While the filing references past acquisitions like AmeriPath and HemoCue which strengthened its position in specialized testing, there were no major new acquisitions highlighted for 2009. The company's focus was on integrating existing capabilities and executing its core strategy.
What are the significant risk factors identified by Quest Diagnostics?
Quest Diagnostics identifies several key risks, including continued weakness in economic conditions, intense competition within the clinical testing industry, potential adverse impacts from healthcare reform, government payer actions to control utilization and reimbursement, healthcare plan pressures on utilization and reimbursement, challenges in integrating acquired businesses, and the need to continuously improve efficiency. Failure to comply with numerous legal and regulatory requirements is also a significant concern.
06—Continue